HC Wainwright Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

HC Wainwright reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report released on Monday, Benzinga reports. HC Wainwright currently has a $60.00 price objective on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q2 2024 earnings at ($0.77) EPS, Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($3.16) EPS, Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.72) EPS.

Several other analysts also recently weighed in on the company. Oppenheimer upped their price objective on UroGen Pharma from $32.00 to $40.00 and gave the stock an outperform rating in a research report on Friday, June 14th. LADENBURG THALM/SH SH upped their price objective on UroGen Pharma from $48.00 to $53.50 and gave the stock a buy rating in a research report on Friday, June 14th.

UroGen Pharma Price Performance

URGN opened at $15.01 on Monday. The business has a fifty day simple moving average of $14.42 and a 200 day simple moving average of $15.26. The company has a market capitalization of $351.98 million, a PE ratio of -4.41 and a beta of 1.12. UroGen Pharma has a 1 year low of $8.69 and a 1 year high of $24.13.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The firm had revenue of $18.78 million during the quarter, compared to analysts’ expectations of $20.73 million. Equities analysts anticipate that UroGen Pharma will post -3.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 5,153 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $13.08, for a total value of $67,401.24. Following the transaction, the insider now owns 144,284 shares in the company, valued at $1,887,234.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.13% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Several hedge funds have recently made changes to their positions in URGN. Superstring Capital Management LP purchased a new position in UroGen Pharma during the 4th quarter valued at about $3,831,000. Sierra Summit Advisors LLC purchased a new position in shares of UroGen Pharma during the 4th quarter worth approximately $218,000. Jump Financial LLC grew its holdings in shares of UroGen Pharma by 12.6% during the 4th quarter. Jump Financial LLC now owns 33,320 shares of the company’s stock worth $500,000 after acquiring an additional 3,720 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of UroGen Pharma by 361.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after acquiring an additional 2,801 shares during the period. Finally, RTW Investments LP grew its holdings in shares of UroGen Pharma by 101.4% during the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after acquiring an additional 869,344 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.